Lymphoma relapse 1 year or later after immunochemotherapy in DLBCL patients: clinical features and outcome

作者：Hongyun Chen, Jinrong Zhao, Danqing Zhao, Wei Wang, Chong Wei, Zi Wang, Daobin Zhou, Wei Zhang · 发表于：Clinical and Experimental Medicine · 年份：2024 · DOI：10.1007/s10238-024-01306-2 · 被引用次数：7 · 研究领域：CAR-T cell therapy research、Lymphoma Diagnosis and Treatment、CNS Lymphoma Diagnosis and Treatment

Despite great advances in treatment, 30-40% of patients with DLBCL undergo relapses. Patients with a relapse within 1 year or beyond have a distinct outcome. Few clinical characteristics and survival data in the Chinese population have been published. We aimed to define the incidence and clinical features of DLBCL patients with very early relapse after front-line immunochemotherapy who may benefit greatly from the emerging chimeric antigen receptor T-cell therapy. Data of 564 DLBCL patients were analyzed. Among the 413 patients achieving a first complete remission, 59 underwent relapses: 32 patients (54.2%) relapsed within 1 year, and 27 patients (46.8%) relapsed 1 year or more. Patients relapsing within 1 year, in comparison with the other group, showed an inferior risk profile at diagnosis: elevated lactate dehydrogenase level (P = 0.002), high Eastern Cooperative Oncology Group performance score (P = 0.02), and high international prognosis index (P = 0.004). As expected, a worse overall survival was observed in the early relapse group. Multivariate analysis for OS showed that relapse within 1 year was an independent parameter for reduced overall survival (HR 0.241, P = 0.002).